Intervention

SHR6390

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 12 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials12
Recruiting0
Common conditions10
Lead sponsors shown7
Advertisement

Clinical trials

12 shown
Study of SHR6390 in Renal Insufficiency and Healthy SubjectsNCT05515289 · 2022-12-18
UNKNOWN
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02NCT05205200 · 2022-06-06
UNKNOWN
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerNCT05176080 · 2021-12-08
TERMINATED
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.NCT04733417 · 2021-05-26
UNKNOWN
Phase III Study :SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeNCT04842617 · 2021-04-30
ACTIVE_NOT_RECRUITING
Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerNCT04355858 · 2020-05-01
UNKNOWN
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast CancerNCT04293276 · 2020-04-01
UNKNOWN
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.NCT04236310 · 2020-01-15
UNKNOWN
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast CancerNCT04095390 · 2019-09-30
UNKNOWN
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerNCT03927456 · 2019-06-13
UNKNOWN
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCCNCT03601598 · 2018-07-30
UNKNOWN
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerNCT03481998 · 2018-03-22
COMPLETED

Trial status mix

UNKNOWN9
ACTIVE_NOT_RECRUITING1
COMPLETED1
TERMINATED1

Phase mix

PHASE29
PHASE14
PHASE32
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.